Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507707 | 1.00 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL3865022 | 0.90 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL3861955 | 0.87 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| Methane SCHEMBL3862512 | 0.87 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL4552462 | 0.86 | TLR7 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL25396713 | 0.84 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL3870527 | 0.83 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL3863927 | 0.82 | TLR7 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL29373790 | 0.82 | TLR7 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL3865783 | 0.81 | TLR7 (0.56) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | claimed |
| US-20220089749-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885TLR8 1153/4885NUDT1 3504/4885 |
| US-20220089749-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | EGFR, ERBB3, ERBB2 | TLR7 2007/4885TLR8 1153/4885NUDT1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.